News

U.S. tracking of HPV in cervical precancers confirms half due to 16/18


 

FROM AN ACIP MEETING

As ACIP members met, Sanofi Pasteur announced that its quadrivalent HPV vaccine, Gardasil, was one step closer to receiving European approval for a two-dose schedule (0, 6 months) in girls and boys aged 9-13 years.

Finally, ACIP’s members unanimously affirmed efforts to update its 2007 HPV vaccine statement. The new statement, which still needs to go through editing before a final vote, consolidates and clarifies existing recommendations and updates background and clinical trial data. It also adds a variety of new sections including postlicensure safety data, areas of ongoing research, and future priorities, including the 9-valent vaccine and reduced-dose schedules, she said.

Dr. Hariri and Dr. Markowitz reported having no financial disclosures. Dr. Luxembourg is an employee of Merck.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

VIDEO: Investigational topical antifungals target onychomycosis
MDedge Dermatology
VIDEO: A new look at three common pediatric dermatology presentations
MDedge Dermatology
VIDEO: Treatment tips for pediatric molluscum contagiosum
MDedge Dermatology
VIDEO: New and upcoming topical antifungals
MDedge Dermatology
FDA vaccines panel: Retain current strains in next season’s influenza vaccines
MDedge Dermatology
CDC sounds alarm on hospital antibiotic use
MDedge Dermatology
HIV-1 has gained virulence over the course of the epidemic
MDedge Dermatology
Risk of condomless sex low if HIV-positive partner is well controlled on ART
MDedge Dermatology
Cosmetic Corner: Dermatologists Weigh in on OTC Antifungals
MDedge Dermatology
FDA panel unanimously backs cobas HPV test as primary screening tool
MDedge Dermatology

Related Articles